Berlin, Germany – A French medical device company specializing in remote cancer patient monitoring, Continuum Plus Santé, faces potential changes to its reimbursement status in France. Whereas the company recently secured official coverage for its Continuum+ Connect digital medical device for oncological telehealth, questions are emerging about the long-term financial viability of this support. The situation highlights the complexities of integrating innovative digital health solutions into established healthcare systems.
Continuum+ Connect is designed to facilitate the remote surveillance of adult cancer patients undergoing systemic treatment. The device and associated platform aim to improve patient care by enabling healthcare professionals to interpret clinical constants, symptoms, and side effects, generating alerts when intervention is needed. The company offers three modes of support: through liberal nurses, pharmacy professionals, and patient self-evaluation, tailoring the level of assistance to individual patient needs. This personalized approach is a key feature of the Continuum+ system, aiming to enhance both patient outcomes and the efficiency of oncology care.
Initial Reimbursement Success and Subsequent Concerns
In August 2024, the French National Commission for the Evaluation of Medical Devices and Health Technologies (Cnedimts) issued a favorable opinion for early reimbursement (Peca) of Continuum+ Connect. This decision followed a previous rejection of the device’s registration under its brand name in 2023, demonstrating the evolving assessment of digital health technologies by French regulatory bodies. The positive Peca ruling was a significant win for Continuum Plus Santé, signaling recognition of the potential benefits of remote monitoring in oncology. However, recent developments suggest this support may be reconsidered.
The initial optimism surrounding the Peca approval is now tempered by reports indicating a potential finish to the reimbursement arrangement. While the exact reasons for this shift are still emerging, it underscores the challenges faced by digital health companies in navigating the complexities of healthcare funding and demonstrating long-term value. The French healthcare system, like many others, is under increasing pressure to control costs while maintaining quality of care, leading to rigorous scrutiny of new technologies and their associated expenses.
How Continuum+ Connect Works: A Three-Pronged Approach
Continuum+ Connect distinguishes itself through its flexible approach to patient monitoring. The company’s platform offers three distinct modalities, allowing healthcare providers to select the most appropriate level of support for each patient:
- Follow-up by the liberal nurse: Nurses provide direct monitoring and support to patients, offering a personalized touch and addressing individual needs.
- Follow-up by the pharmacy professional: Pharmacists play a role in monitoring patients, leveraging their expertise in medication management and side effect monitoring.
- Self-assessment by the patient: Patients actively participate in their own care by regularly reporting their symptoms and well-being through the platform.
This tiered system aims to optimize resource allocation and ensure that patients receive the level of support they require, without overburdening healthcare professionals. The platform itself is designed to interpret clinical data, identify potential issues, and generate alerts, enabling timely intervention and improved patient outcomes. Continuum+ Connect is intended to be a comprehensive solution, integrating seamlessly into existing oncology workflows.
The Role of Digital Technology in Cancer Care
The rise of digital health technologies like Continuum+ Connect reflects a broader trend towards remote patient monitoring and personalized medicine. Telehealth has gained significant traction in recent years, accelerated by the COVID-19 pandemic, and is now seen as a valuable tool for improving access to care, reducing healthcare costs, and enhancing patient engagement. In oncology, remote monitoring can be particularly beneficial for managing side effects, detecting early signs of complications, and providing emotional support to patients undergoing challenging treatments.
However, the integration of digital health solutions is not without its challenges. Concerns about data privacy, cybersecurity, and the digital divide must be addressed to ensure equitable access and build trust among patients and healthcare providers. Demonstrating the clinical and economic value of these technologies is crucial for securing long-term reimbursement and widespread adoption. The case of Continuum+ Connect highlights the need for ongoing evaluation and adaptation to ensure that digital health solutions deliver on their promise.
Impact on Patients and Healthcare Providers
A potential withdrawal of reimbursement for Continuum+ Connect could have significant implications for both patients and healthcare providers. For patients, it could limit access to a valuable tool for managing their cancer treatment and monitoring their well-being. For healthcare providers, it could disrupt established workflows and potentially compromise the quality of care they are able to provide. The uncertainty surrounding the reimbursement status creates challenges for planning and resource allocation within oncology departments.
The French Society of Oncology (SFRO) and other professional organizations have been vocal advocates for the integration of digital health technologies into cancer care. They argue that these tools can improve patient outcomes, reduce healthcare costs, and enhance the efficiency of oncology services. The SFRO’s position underscores the importance of continued investment in digital health innovation and the need for a supportive regulatory environment.
Recent Developments and Regulatory Scrutiny
On March 3, 2026, the French Haute Autorité de Santé (HAS) published an assessment of Continuum+ Connect as a digital medical device for remote medical monitoring of adult cancer patients undergoing systemic treatment. This assessment further underscores the ongoing scrutiny of the device and its potential impact on the French healthcare system. The HAS evaluation will likely play a key role in shaping future reimbursement decisions.
The evolving regulatory landscape surrounding Continuum+ Connect reflects a broader trend towards greater accountability and transparency in the digital health sector. Regulatory bodies are increasingly focused on ensuring that digital health technologies are safe, effective, and cost-effective before granting widespread reimbursement. This rigorous evaluation process is essential for protecting patients and ensuring that healthcare resources are used wisely.
What Happens Next?
The future of Continuum+ Connect’s reimbursement status remains uncertain. The company is likely to engage in discussions with French healthcare authorities to address concerns and advocate for continued support. The outcome of these discussions will depend on a variety of factors, including the results of the HAS assessment, the evolving budgetary priorities of the French government, and the demonstrated clinical and economic value of the device.
Stakeholders will be closely watching for further announcements from the French Ministry of Health and the Cnedimts. The decision regarding Continuum+ Connect could set a precedent for other digital health companies seeking reimbursement in France, and beyond. It will also shape the future of remote cancer care and the role of digital technology in improving patient outcomes.
The next key checkpoint is expected to be a formal announcement from the French Ministry of Health regarding the future of the Peca approval for Continuum+ Connect, anticipated within the next quarter. We encourage readers to share their thoughts and experiences with digital health technologies in the comments below.
Keep reading